224 related articles for article (PubMed ID: 21378393)
1. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts.
Bastin J; Lopes-Costa A; Djouadi F
Hum Mol Genet; 2011 May; 20(10):2048-57. PubMed ID: 21378393
[TBL] [Abstract][Full Text] [Related]
2. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
Djouadi F; Aubey F; Schlemmer D; Ruiter JP; Wanders RJ; Strauss AW; Bastin J
Hum Mol Genet; 2005 Sep; 14(18):2695-703. PubMed ID: 16115821
[TBL] [Abstract][Full Text] [Related]
3. Next generation sequencing of RNA reveals novel targets of resveratrol with possible implications for Canavan disease.
Dembic M; Andersen HS; Bastin J; Doktor TK; Corydon TJ; Sass JO; Lopes Costa A; Djouadi F; Andresen BS
Mol Genet Metab; 2019 Jan; 126(1):64-76. PubMed ID: 30446350
[TBL] [Abstract][Full Text] [Related]
4. Stilbenes and resveratrol metabolites improve mitochondrial fatty acid oxidation defects in human fibroblasts.
Aires V; Delmas D; Le Bachelier C; Latruffe N; Schlemmer D; Benoist JF; Djouadi F; Bastin J
Orphanet J Rare Dis; 2014 Jun; 9():79. PubMed ID: 24898617
[TBL] [Abstract][Full Text] [Related]
5. Long-chain fatty acid oxidation during early human development.
Oey NA; den Boer ME; Wijburg FA; Vekemans M; Augé J; Steiner C; Wanders RJ; Waterham HR; Ruiter JP; Attié-Bitach T
Pediatr Res; 2005 Jun; 57(6):755-9. PubMed ID: 15845636
[TBL] [Abstract][Full Text] [Related]
6. Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate.
Djouadi F; Bonnefont JP; Thuillier L; Droin V; Khadom N; Munnich A; Bastin J
Pediatr Res; 2003 Oct; 54(4):446-51. PubMed ID: 12840153
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol-Induced Changes in MicroRNA Expression in Primary Human Fibroblasts Harboring Carnitine-Palmitoyl Transferase-2 Gene Mutation, Leading to Fatty Acid Oxidation Deficiency.
Aires V; Delmas D; Djouadi F; Bastin J; Cherkaoui-Malki M; Latruffe N
Molecules; 2017 Dec; 23(1):. PubMed ID: 29271911
[TBL] [Abstract][Full Text] [Related]
8. A new AMPK activator, GSK773, corrects fatty acid oxidation and differentiation defect in CPT2-deficient myotubes.
Boufroura FZ; Le Bachelier C; Tomkiewicz-Raulet C; Schlemmer D; Benoist JF; Grondin P; Lamotte Y; Mirguet O; Mouillet-Richard S; Bastin J; Djouadi F
Hum Mol Genet; 2018 Oct; 27(19):3417-3433. PubMed ID: 30007356
[TBL] [Abstract][Full Text] [Related]
9. Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet.
Alberdi G; Rodríguez VM; Macarulla MT; Miranda J; Churruca I; Portillo MP
Nutrition; 2013 Mar; 29(3):562-7. PubMed ID: 23274094
[TBL] [Abstract][Full Text] [Related]
10. Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs?
Djouadi F; Aubey F; Schlemmer D; Gobin S; Laforet P; Wanders RJ; Strauss AW; Bonnefont JP; Bastin J
J Inherit Metab Dis; 2006; 29(2-3):341-2. PubMed ID: 16763897
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells.
Djouadi F; Aubey F; Schlemmer D; Bastin J
J Clin Endocrinol Metab; 2005 Mar; 90(3):1791-7. PubMed ID: 15613406
[TBL] [Abstract][Full Text] [Related]
12. Characterization of L-aminocarnitine, an inhibitor of fatty acid oxidation.
Chegary M; Te Brinke H; Doolaard M; Ijlst L; Wijburg FA; Wanders RJ; Houten SM
Mol Genet Metab; 2008 Apr; 93(4):403-10. PubMed ID: 18077198
[TBL] [Abstract][Full Text] [Related]
13. Effect of heat stress and bezafibrate on mitochondrial beta-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay.
Li H; Fukuda S; Hasegawa Y; Kobayashi H; Purevsuren J; Mushimoto Y; Yamaguchi S
Brain Dev; 2010 May; 32(5):362-70. PubMed ID: 19589653
[TBL] [Abstract][Full Text] [Related]
14. Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy.
Gobin-Limballe S; Djouadi F; Aubey F; Olpin S; Andresen BS; Yamaguchi S; Mandel H; Fukao T; Ruiter JP; Wanders RJ; McAndrew R; Kim JJ; Bastin J
Am J Hum Genet; 2007 Dec; 81(6):1133-43. PubMed ID: 17999356
[TBL] [Abstract][Full Text] [Related]
15. Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay.
Yamaguchi S; Li H; Purevsuren J; Yamada K; Furui M; Takahashi T; Mushimoto Y; Kobayashi H; Hasegawa Y; Taketani T; Fukao T; Fukuda S
Mol Genet Metab; 2012 Sep; 107(1-2):87-91. PubMed ID: 22841441
[TBL] [Abstract][Full Text] [Related]
16. Myocardial infarction in rats causes partial impairment in insulin response associated with reduced fatty acid oxidation and mitochondrial gene expression.
Amorim PA; Nguyen TD; Shingu Y; Schwarzer M; Mohr FW; Schrepper A; Doenst T
J Thorac Cardiovasc Surg; 2010 Nov; 140(5):1160-7. PubMed ID: 20850803
[TBL] [Abstract][Full Text] [Related]
17. PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders.
Djouadi F; Bastin J
J Inherit Metab Dis; 2008 Apr; 31(2):217-25. PubMed ID: 18392740
[TBL] [Abstract][Full Text] [Related]
18. Food withdrawal lowers energy expenditure and induces inactivity in long-chain fatty acid oxidation-deficient mouse models.
Diekman EF; van Weeghel M; Wanders RJ; Visser G; Houten SM
FASEB J; 2014 Jul; 28(7):2891-900. PubMed ID: 24648546
[TBL] [Abstract][Full Text] [Related]
19. No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: A randomized clinical cross-over trial.
Storgaard JH; Løkken N; Madsen KL; Voermans NC; Laforêt P; Nadaj-Pakleza A; Tard C; van Hall G; Vissing J; Ørngreen MC
J Inherit Metab Dis; 2022 May; 45(3):517-528. PubMed ID: 35066899
[TBL] [Abstract][Full Text] [Related]
20. Medium branched chain fatty acids improve the profile of tricarboxylic acid cycle intermediates in mitochondrial fatty acid β-oxidation deficient cells: A comparative study.
Karunanidhi A; Van't Land C; Rajasundaram D; Grings M; Vockley J; Mohsen AW
J Inherit Metab Dis; 2022 May; 45(3):541-556. PubMed ID: 35076099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
